Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Diabetes

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 74 articles:
HTML format
Text format



Single Articles


    May 2018
  1. MOIST L
    In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization.
    Ann Intern Med. 2018;168:JC52.
    PubMed     Text format    


    April 2018
  2. BEKIARI E, Karagiannis T, Tsapas A
    In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER.
    Ann Intern Med. 2018;168:JC46.
    PubMed     Text format    


  3. VIGERSKY RA
    Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections.
    Ann Intern Med. 2018;168:528.
    PubMed     Text format    


  4. BECK RW, Riddlesworth TD
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:526-527.
    PubMed     Text format    


  5. HAAK T
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections.
    Ann Intern Med. 2018;168:525-526.
    PubMed     Text format    


  6. CHAMBERLAIN JJ, Johnson EL, Leal S, Rhinehart AS, et al
    Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
    Ann Intern Med. 2018 Apr 3. pii: 2677350. doi: 10.7326/M18-0222.
    PubMed     Text format     Abstract available


    March 2018
  7. GOEL A
    Intensive weight management in primary care improved weight loss and remission of type 2 diabetes.
    Ann Intern Med. 2018;168:JC30.
    PubMed     Text format    



  8. Hemoglobin A1c Targets for Nonpregnant Adults With Type 2 Diabetes Mellitus.
    Ann Intern Med. 2018 Mar 6. pii: 2674123. doi: 10.7326/P18-0003.
    PubMed     Text format    


  9. QASEEM A, Wilt TJ, Kansagara D, Horwitch C, et al
    Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians.
    Ann Intern Med. 2018 Mar 6. pii: 2674121. doi: 10.7326/M17-0939.
    PubMed     Text format     Abstract available


    January 2018
  10. GENERE N, Montori VM
    Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas.
    Ann Intern Med. 2018;168:JC8.
    PubMed     Text format    


    December 2017
  11. LIPSCOMBE LL
    Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes.
    Ann Intern Med. 2017;167:JC67.
    PubMed     Text format    


  12. LIPSCOMBE LL
    Liraglutide reduced a composite renal outcome at a median 4 y in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;167:JC66.
    PubMed     Text format    



  13. Cost-Effectiveness of Individualized Management of Diabetes Among U.S. Adults.
    Ann Intern Med. 2017 Dec 12. pii: 2665905. doi: 10.7326/P17-9050.
    PubMed     Text format    


  14. LAITEERAPONG N, Cooper JM, Skandari MR, Clarke PM, et al
    Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.
    Ann Intern Med. 2017 Dec 12. pii: 2665902. doi: 10.7326/M17-0537.
    PubMed     Text format     Abstract available


    October 2017
  15. SELVIN E, Wang D, Lee AK, Bergenstal RM, et al
    Identifying Trends in Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A Cross-sectional Study.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1272.
    PubMed     Text format     Abstract available


  16. CONLIN PR, Colburn J, Aron D, Pries RM, et al
    Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-1362.
    PubMed     Text format     Abstract available


  17. PETERS AL
    Rethinking Rates of Undiagnosed Diabetes: The Value of a Confirmatory Test.
    Ann Intern Med. 2017 Oct 24. doi: 10.7326/M17-2576.
    PubMed     Text format    


  18. DASGUPTA I, Singh AK
    Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death.
    Ann Intern Med. 2017;167:JC47.
    PubMed     Text format    


  19. MURFF HJ
    Self-monitoring of blood glucose did not improve HbA1c or QoL at 1 year in non-insulin-treated type 2 diabetes.
    Ann Intern Med. 2017;167:JC46.
    PubMed     Text format    


    September 2017
  20. CHAMBERLAIN JJ, Kalyani RR, Leal S, Rhinehart AS, et al
    Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Sep 12. doi: 10.7326/M17-1259.
    PubMed     Text format     Abstract available


    August 2017
  21. ARGUELLO V, Freeby M
    Continuous Glucose Monitoring in Patients With Type 2 Diabetes Receiving Insulin Injections: Does This Mean Continuous Glucose Monitoring for Everyone?
    Ann Intern Med. 2017 Aug 22. doi: 10.7326/M17-2121.
    PubMed     Text format    



  22. Continuous Glucose Monitoring in Patients With Type 2 Diabetes.
    Ann Intern Med. 2017 Aug 22. doi: 10.7326/P17-9044.
    PubMed     Text format    


  23. BECK RW, Riddlesworth TD, Ruedy K, Ahmann A, et al
    Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial.
    Ann Intern Med. 2017 Aug 22. doi: 10.7326/M16-2855.
    PubMed     Text format     Abstract available



  24. Correction: Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals.
    Ann Intern Med. 2017;167:292.
    PubMed     Text format    


  25. LIPSCOMBE LL
    In type 1 diabetes, education with either insulin pumps or daily injections did not differ for HbA1c at 2 y.
    Ann Intern Med. 2017;167:JC15.
    PubMed     Text format    


    July 2017
  26. NGUYEN JT, Molony DA
    Review: Dapagliflozin increases, and empagliflozin reduces, adverse renal events in type 2 diabetes.
    Ann Intern Med. 2017;167:JC5.
    PubMed     Text format    


  27. BERGENSTAL RM, Gal RL, Connor CG, Gubitosi-Klug R, et al
    Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels.
    Ann Intern Med. 2017;167:95-102.
    PubMed     Text format     Abstract available


  28. BARRY MJ, Humphrey LL, Qaseem A
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017;167:75-76.
    PubMed     Text format    


  29. BELL DSH
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017;167:74-75.
    PubMed     Text format    


  30. INZUCCHI SE, Kosiborod M
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
    Ann Intern Med. 2017;167:73-74.
    PubMed     Text format    


  31. JACK MM
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;167:72.
    PubMed     Text format    


  32. SLAVIN J
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;167:71-72.
    PubMed     Text format    


  33. SCHILLINGER D, Kearns C
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;167:72-73.
    PubMed     Text format    


    May 2017
  34. RUSHAKOFF RJ, Sullivan MM, MacMaster HW, Shah AD, et al
    Association Between a Virtual Glucose Management Service and Glycemic Control in Hospitalized Adult Patients: An Observational Study.
    Ann Intern Med. 2017;166:621-627.
    PubMed     Text format     Abstract available


    April 2017
  35. JASIM S, Smith SA
    Review: Metformin is linked to reduced mortality in type 2 diabetes with comorbid CKD and CHF.
    Ann Intern Med. 2017;166:JC46.
    PubMed     Text format    


  36. RODRIGUEZ-GUTIERREZ R, Montori VM
    Guideline: In type 2 diabetes, ACP recommends metformin monotherapy if drugs are needed for glycemic control.
    Ann Intern Med. 2017;166:JC39.
    PubMed     Text format    


  37. PETERSEN MP, Ratner RE
    Should We Screen for Type 2 Diabetes?
    Ann Intern Med. 2017;166:535.
    PubMed     Text format    


  38. RIND DM
    Should We Screen for Type 2 Diabetes?
    Ann Intern Med. 2017;166:535-536.
    PubMed     Text format    


    March 2017
  39. CHAMBERLAIN JJ, Herman WH, Leal S, Rhinehart AS, et al
    Pharmacologic Therapy for Type 2 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes.
    Ann Intern Med. 2017 Mar 14. doi: 10.7326/M16-2937.
    PubMed     Text format     Abstract available


    February 2017
  40. BACH RG
    Review: Long-term dual-antiplatelet therapy (DAPT) after PCI is no better than short-term DAPT, even with diabetes.
    Ann Intern Med. 2017;166:JC22.
    PubMed     Text format    



  41. Correction: Do Sugar-Sweetened Beverages Cause Obesity and Diabetes?
    Ann Intern Med. 2017;166:232.
    PubMed     Text format    


    January 2017
  42. DONATO AA
    Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
    Ann Intern Med. 2017;166:JC8.
    PubMed     Text format    


  43. BROPHY J
    Review: In type 2 diabetes, sodium-glucose cotransporter 2 inhibitors do not increase major CV events or mortality.
    Ann Intern Med. 2017;166:JC7.
    PubMed     Text format    


  44. QASEEM A, Barry MJ, Humphrey LL, Forciea MA, et al
    Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
    Ann Intern Med. 2017 Jan 3. doi: 10.7326/M16-1860.
    PubMed     Text format     Abstract available



  45. Oral Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2017 Jan 3. doi: 10.7326/P16-9028.
    PubMed     Text format    


  46. FRADKIN JE, Rodgers GP
    Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind.
    Ann Intern Med. 2017 Jan 3. doi: 10.7326/M16-2883.
    PubMed     Text format    


    December 2016
  47. TANNER M
    In type 1 diabetes, adding liraglutide to insulin increased hypoglycemia and hyperglycemia with ketosis.
    Ann Intern Med. 2016;165:JC64.
    PubMed     Text format    


  48. PETERSON KA
    Balancing Primary Diabetes Care Quality and Services.
    Ann Intern Med. 2016 Dec 13. doi: 10.7326/M16-2768.
    PubMed     Text format    


  49. CHEUNG A, Stukel TA, Alter DA, Glazier RH, et al
    Primary Care Physician Volume and Quality of Diabetes Care: A Population-Based Cohort Study.
    Ann Intern Med. 2016 Dec 13. doi: 10.7326/M16-1056.
    PubMed     Text format     Abstract available


    November 2016
  50. MURFF HJ
    Review: In adults with diabetes, aspirin does not prevent CV events compared with placebo.
    Ann Intern Med. 2016;165:JC53.
    PubMed     Text format    


  51. SCHILLINGER D, Tran J, Mangurian C, Kearns C, et al
    Do Sugar-Sweetened Beverages Cause Obesity and Diabetes? Industry and the Manufacture of Scientific Controversy.
    Ann Intern Med. 2016 Nov 1. doi: 10.7326/L16-0534.
    PubMed     Text format    


    October 2016
  52. GONZALES K, Gandhi GY
    In type 2 diabetes treated with high-dose insulin, liraglutide reduced HBA1c.
    Ann Intern Med. 2016;165:JC40.
    PubMed     Text format    


  53. PATEL T
    In patients with type 2 diabetes and CVD, empagliflozin reduced incident or worsening nephropathy at 3.1 y.
    Ann Intern Med. 2016;165:JC39.
    PubMed     Text format    


  54. MAZUREK M, Lip GY
    In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
    Ann Intern Med. 2016;165:JC38.
    PubMed     Text format    


  55. SMETANA GW, Abrahamson MJ, Rind DM
    Should We Screen for Type 2 Diabetes?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2016;165:509-516.
    PubMed     Text format     Abstract available


    September 2016
  56. STEINBERG DI
    Intensive glucose-lowering in type 2 diabetes was linked to hypoglycemia in high-complexity patients.
    Ann Intern Med. 2016;165:JC33.
    PubMed     Text format    


    August 2016
  57. TANNER M
    Review: In type 2 diabetes, adding dipeptidyl peptidase-4 inhibitors to sulphonylureas increases hypoglycemia.
    Ann Intern Med. 2016;165:JC20.
    PubMed     Text format    


  58. GUNDERSON EP
    Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus.
    Ann Intern Med. 2016;165:299-300.
    PubMed     Text format    


  59. NAGAHORI W, Takenoshita H, Yuki K, Kimachi M, et al
    Lactation and Progression to Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus.
    Ann Intern Med. 2016;165:299.
    PubMed     Text format    


  60. LOPEZ D, Luque-Fernandez MA, Steele A, Adler GK, et al
    "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study.
    Ann Intern Med. 2016 Aug 2. doi: 10.7326/M16-0547.
    PubMed     Text format     Abstract available


  61. SIU AL
    Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus.
    Ann Intern Med. 2016;165:225.
    PubMed     Text format    


  62. BARKOUDAH E, Weinrauch LA
    Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus.
    Ann Intern Med. 2016;165:225.
    PubMed     Text format    



  63. Assessing the Risk for Diabetes in Patients With Unexpectedly Identified Tumors in the Adrenal Glands.
    Ann Intern Med. 2016 Aug 2. doi: 10.7326/P16-9020.
    PubMed     Text format    


    July 2016
  64. SFEIR JG, Montori VM
    In insulin-treated type 1 diabetes, canagliflozin increased diabetic ketoacidosis.
    Ann Intern Med. 2016;165:JC2.
    PubMed     Text format    


  65. ALI MK, Singh K, Kondal D, Devarajan R, et al
    Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals: A Randomized, Controlled Trial.
    Ann Intern Med. 2016 Jul 12. doi: 10.7326/M15-2807.
    PubMed     Text format     Abstract available


  66. BRAILLON A
    Moderate Alcohol Intake and Cardiometabolic Risk in Adults With Type 2 Diabetes.
    Ann Intern Med. 2016;165:68.
    PubMed     Text format    


  67. ALTMAN DG
    Moderate Alcohol Intake and Cardiometabolic Risk in Adults With Type 2 Diabetes.
    Ann Intern Med. 2016;165:67-8.
    PubMed     Text format    


  68. SAITZ R, Naimi T
    Moderate Alcohol Intake and Cardiometabolic Risk in Adults With Type 2 Diabetes.
    Ann Intern Med. 2016;165:67.
    PubMed     Text format    


    June 2016
  69. MANTILLA LL, Montori VM
    Review: In diabetes, benefits of lowering BP depend on baseline BP being 140 mm Hg or more.
    Ann Intern Med. 2016;164:JC62.
    PubMed     Text format    



  70. Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
    Ann Intern Med. 2016 Jun 21. doi: 10.7326/P16-9018.
    PubMed     Text format    


  71. VILAR-GOMEZ E, Adams LA
    Pioglitazone: An Addition to Our Toolbox for Patients With Diabetes and Nonalcoholic Steatohepatitis?
    Ann Intern Med. 2016 Jun 21. doi: 10.7326/M16-1303.
    PubMed     Text format    


  72. CUSI K, Orsak B, Bril F, Lomonaco R, et al
    Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Ann Intern Med. 2016 Jun 21. doi: 10.7326/M15-1774.
    PubMed     Text format     Abstract available


    April 2016
  73. MOREIRA AM, Londero TM, Goemann IM, Schaan BD, et al
    Cardiometabolic Effects of CASCADE Trial Explained by Mediterranean Diet.
    Ann Intern Med. 2016;164:573-4.
    PubMed     Text format    


    March 2016
  74. FREUND T, Peters-Klimm F, Boyd CM, Mahler C, et al
    Medical Assistant-Based Care Management for High-Risk Patients in Small Primary Care Practices: A Cluster Randomized Clinical Trial.
    Ann Intern Med. 2016;164:323-30.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: